Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities

0
  • Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. J Am Med Assoc. 2022;327:464–77.

    Article 
    CAS 

    Google Scholar 

  • Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:606.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9:3.

  • Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36:801–8.

    Article 
    PubMed 

    Google Scholar 

  • Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Surveillance. Epidemiology, and End Results (SEER) Program Populations (1969-2020). National Cancer Institute, DCCPS, Surveillance Research Program; 2023. www.seer.cancer.gov/popdata.

  • Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transpl. 2019;54:353–67.

    Article 
    CAS 

    Google Scholar 

  • Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017;6:2876–85.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer. 2017;123:3141–9.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158:91–8.

    Article 
    PubMed 

    Google Scholar 

  • Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, et al. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities. Cancer. 2018;124:1710–21.

    Article 
    PubMed 

    Google Scholar 

  • Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019;3:2986–94.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BC. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020;10:80.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017;123:1590–6.

    Article 
    PubMed 

    Google Scholar 

  • Bhutani M, Blue BJ, Cole C, Badros AZ, Usmani SZ, Nooka AK, et al. Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer J. 2023;13:189.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ailawadhi S, Bhatia K, Aulakh S, Meghji Z, Chanan-Khan A. Equal treatment and outcomes for everyone with multiple myeloma: are we there yet? Curr Hematol Malig Rep. 2017;12:309–16.

    Article 
    PubMed 

    Google Scholar 

  • Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, et al. Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care. JCO Oncol Pract. 2020;16:e341–e9.

    Article 
    PubMed 

    Google Scholar 

  • Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6:e486.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1:282–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Maignan K, Fashoyin-Aje LA, Torres AZ, Fernandes LL, Gwise T, Baxi SB, et al. Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data. Blood Cancer J. 2022;12:65.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013;121:3147–52.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Peres LC, Oswald LB, Dillard C, De Avila G, Nishihori T, Blue BJ, et al. Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy. Blood. 2022;140:623–5.

    Article 

    Google Scholar 

  • Pulte D, Redaniel MT, Brenner H, Jansen L, Jeffreys M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma. 2014;55:1083–9.

    Article 
    PubMed 

    Google Scholar 

  • Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, et al. Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 2020;126:5077–87.

    Article 
    PubMed 

    Google Scholar 

  • McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic status and access to healthcare: interrelated drivers for healthy aging. Front Public Health. 2020;8:231.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Care Without Coverage: Too Little, Too Late. Washington (DC): National Academic Press (US); 2002.

  • Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, et al. Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol. 2023;98:41–8.

    Article 
    PubMed 

    Google Scholar 

  • Doucette K, Taylor AO, Chan B, Ma X, Ahn J, Vesole DH, et al. Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis. Ann Hematol. 2023;102:1443–58.

    Article 
    PubMed 

    Google Scholar 

  • Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89:825–30.

    Article 
    PubMed 

    Google Scholar 

  • link

    Leave a Reply

    Your email address will not be published. Required fields are marked *